Cargando…

MRI-targeted prostate biopsy: the next step forward!

AIM: For decades, the gold standard technique for diagnosing prostate cancer was the 10 to 12 core systematic transrectal or transperineal biopsy, under ultrasound guidance. Over the past years, an increased rate of false negative results and detection of clinically insignificant prostate cancer has...

Descripción completa

Detalles Bibliográficos
Autores principales: Cata, Emanuel Darius, Andras, Iulia, Telecan, Teodora, Tamas-Szora, Attila, Coman, Radu-Tudor, Stanca, Dan-Vasile, Coman, Ioan, Crisan, Nicolae
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Iuliu Hatieganu University of Medicine and Pharmacy 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8118209/
https://www.ncbi.nlm.nih.gov/pubmed/34013185
http://dx.doi.org/10.15386/mpr-1784
_version_ 1783691702702178304
author Cata, Emanuel Darius
Andras, Iulia
Telecan, Teodora
Tamas-Szora, Attila
Coman, Radu-Tudor
Stanca, Dan-Vasile
Coman, Ioan
Crisan, Nicolae
author_facet Cata, Emanuel Darius
Andras, Iulia
Telecan, Teodora
Tamas-Szora, Attila
Coman, Radu-Tudor
Stanca, Dan-Vasile
Coman, Ioan
Crisan, Nicolae
author_sort Cata, Emanuel Darius
collection PubMed
description AIM: For decades, the gold standard technique for diagnosing prostate cancer was the 10 to 12 core systematic transrectal or transperineal biopsy, under ultrasound guidance. Over the past years, an increased rate of false negative results and detection of clinically insignificant prostate cancer has been noted, resulting into overdiagnosis and overtreatment. The purpose of the current study was to evaluate the changes in diagnosis and management of prostate cancer brought by MRI-targeted prostate biopsy. METHODS: A critical review of literature was carried out using the Medline database through a PubMed search, 37 studies meeting the inclusion criteria: prospective studies published in the past 8 years with at least 100 patients per study, which used multiparametric magnetic resonance imaging as guidance for targeted biopsies. RESULTS: In-Bore MRI targeted biopsy and Fusion targeted biopsy outperform standard systematic biopsy both in terms of overall and clinically significant prostate cancer detection, and ensure a lower detection rate of insignificant prostate cancer, with fewer cores needed. In-Bore MRI targeted biopsy performs better than Fusion biopsy especially in cases of apical lesions. CONCLUSION: Targeted biopsy is an emerging and developing technique which offers the needed improvements in diagnosing clinically significant prostate cancer and lowers the incidence of insignificant ones, providing a more accurate selection of the patients for active surveillance and focal therapies.
format Online
Article
Text
id pubmed-8118209
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Iuliu Hatieganu University of Medicine and Pharmacy
record_format MEDLINE/PubMed
spelling pubmed-81182092021-05-18 MRI-targeted prostate biopsy: the next step forward! Cata, Emanuel Darius Andras, Iulia Telecan, Teodora Tamas-Szora, Attila Coman, Radu-Tudor Stanca, Dan-Vasile Coman, Ioan Crisan, Nicolae Med Pharm Rep Review: Urology AIM: For decades, the gold standard technique for diagnosing prostate cancer was the 10 to 12 core systematic transrectal or transperineal biopsy, under ultrasound guidance. Over the past years, an increased rate of false negative results and detection of clinically insignificant prostate cancer has been noted, resulting into overdiagnosis and overtreatment. The purpose of the current study was to evaluate the changes in diagnosis and management of prostate cancer brought by MRI-targeted prostate biopsy. METHODS: A critical review of literature was carried out using the Medline database through a PubMed search, 37 studies meeting the inclusion criteria: prospective studies published in the past 8 years with at least 100 patients per study, which used multiparametric magnetic resonance imaging as guidance for targeted biopsies. RESULTS: In-Bore MRI targeted biopsy and Fusion targeted biopsy outperform standard systematic biopsy both in terms of overall and clinically significant prostate cancer detection, and ensure a lower detection rate of insignificant prostate cancer, with fewer cores needed. In-Bore MRI targeted biopsy performs better than Fusion biopsy especially in cases of apical lesions. CONCLUSION: Targeted biopsy is an emerging and developing technique which offers the needed improvements in diagnosing clinically significant prostate cancer and lowers the incidence of insignificant ones, providing a more accurate selection of the patients for active surveillance and focal therapies. Iuliu Hatieganu University of Medicine and Pharmacy 2021-04 2021-04-29 /pmc/articles/PMC8118209/ /pubmed/34013185 http://dx.doi.org/10.15386/mpr-1784 Text en https://creativecommons.org/licenses/by-nc-nd/4.0/This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (https://creativecommons.org/licenses/by-nc-nd/4.0/)
spellingShingle Review: Urology
Cata, Emanuel Darius
Andras, Iulia
Telecan, Teodora
Tamas-Szora, Attila
Coman, Radu-Tudor
Stanca, Dan-Vasile
Coman, Ioan
Crisan, Nicolae
MRI-targeted prostate biopsy: the next step forward!
title MRI-targeted prostate biopsy: the next step forward!
title_full MRI-targeted prostate biopsy: the next step forward!
title_fullStr MRI-targeted prostate biopsy: the next step forward!
title_full_unstemmed MRI-targeted prostate biopsy: the next step forward!
title_short MRI-targeted prostate biopsy: the next step forward!
title_sort mri-targeted prostate biopsy: the next step forward!
topic Review: Urology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8118209/
https://www.ncbi.nlm.nih.gov/pubmed/34013185
http://dx.doi.org/10.15386/mpr-1784
work_keys_str_mv AT cataemanueldarius mritargetedprostatebiopsythenextstepforward
AT andrasiulia mritargetedprostatebiopsythenextstepforward
AT telecanteodora mritargetedprostatebiopsythenextstepforward
AT tamasszoraattila mritargetedprostatebiopsythenextstepforward
AT comanradutudor mritargetedprostatebiopsythenextstepforward
AT stancadanvasile mritargetedprostatebiopsythenextstepforward
AT comanioan mritargetedprostatebiopsythenextstepforward
AT crisannicolae mritargetedprostatebiopsythenextstepforward